ATS 2019 Virtual Final Program

P277 Identification and PK/PD Assessment of an Oral, Selective, a v b 6 / a v b 1 Dual Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis/ S. Turner, E.I. Lepist, F. Rock, M. Decaris, J. Schaub, C. Chen, P. Andre, South San Francisco, CA, p.A5236 P278 Endoplasmic Reticulum-Mitochondrial Crosstalk in the Development of Idiopathic Pulmonary Fibrosis/ J. Knoell, S. Stich, N. Sommer, C. Ruppert, O. Klymenko, M. Korfei, N. Weissmann, A. Guenther, P. Mahavadi,, Giessen, Germany, p.A5237 P279 Role of ZNF365 in Pulmonary Fibrosis/ J.M. Pérez Huacuja Urista, M. Maldonado, J. Calyeca, R. Ramirez, C. Becerril, M. Selman, A. Pardo, Mexico City, Mexico, p.A5238 Facilitator : R.M. Kottmann, MD, Rochester, NY P280 The Autotaxin Inhibitor GLPG1690 Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice/ A. Murgo, B. Canciani, D. Fragni, E. Donetti, M. Civelli, G. Villetti, D. Miglietta, Parma, Italy, p.A5239 P281 GLUT1-Dependent Glycolysis Regulates Exacerbation of Fibrosis Via AIM2 Inflammasome Activation/ H.S. Yun, R. Harris, H. Hong, A.M.K. Choi, H. Stout-Delgado, S.J. Cho, New York, NY, p.A5240 P282 CHI3L1-CRTH2 Axis Is a Biomarker and Therapeutic Target in Pulmonary Fibrosis/ Y. Zhou, B. Shea, Y. Cao, R. Williams, C. Lee, C. Lee, J.A. Elias, Providence, RI, p.A5241 P283 Cellular Uptake of a Novel siRNA-Based Oligonucleotide, TRK-250 in Lung Cells/ M. Yamada, A. Izawa, A. Shibata, T. Matsumoto, Y. Eguchi, H. Inada, W. Toriumi, Y. Miyamoto, Kamakura, Japan, p.A5242 P284 Autophagy in Lung Fibrosis: Exploring the Mitophagy Pathways/ J. Grodtke, S. Chillappagari, M. Schaefer, C. Ruppert, M. Korfei, A. Guenther, P. Mahavadi, Giessen, Germany, p.A5243 P285 The Role Of CD30 in the Development of Emphysema and Fibrosis in IPF/ Y.A.P.J. Sa, D.M. Habiel, M.S. Espindola, A.L. Coelho, C.M. Hogaboam, Los Angeles, CA, p.A5244 P286 Inhibition of Glutaminolysis Attenuates Pulmonary Fibrosis in Mice/ H. Cui, N. Xie, S. Banerjee, S. Guo, J. Ge, Y.Y. Sanders, G. Liu, Birmingham, AL, p.A5245 Facilitator : A.B. Carter, MD, Birmingham, AL P287 Apolipoprotein E in Recruited Alveolar Macrophages Promotes Lung Fibrosis Resolution/ H. Cui, S. Guo, S. Banerjee, N. Xie, R.-M. Liu, V.J. Thannickal, G. Liu, Birmingham, AL, p.A5246 P288 Macrophage Programs in BAL and Lung Parenchyma of the Healthy and in IPF Patients/ J.C. Schupp, T. Adams, N. Neumark, S. Poli De Frias, F. Ahangari, G. DeIuliis, S. Chu, X. Yan, N. Kaminski, A. Prasse, I.O. Rosas, New Haven, CT, p.A5247 P289 MEK/ERK Inhibitors Affect Epithelial Barrier Function in Cells with Ongoing Active Repair Processes Indicating a Potential Hazard in Patients with Healing Lung/ M. Larsson, K. Balogh Sivars, M. Forsgard, M. Parsson, J. Hornberg, Gothenburg, Sweden, p.A5248 P290 Ablation/Inhibition of Protein Disulfide Isomerase A3 Improves Pulmonary Fibrosis in Mice/ A. Kumar, E. Elko, Z.F. Mark, Y.M.W. Janssen-Heininger, V. Anathy, Burlington, VT, p.A5249 P291 CXCR4 Inhibition by the I-Body Ad-114 Blocks Bronchosphere Formation in a 3d Organoid Model/ B. Jäger, A. Schambach, K. Denise, M. Foley, A. Prasse, Hannover, Germany, p.A5250 P292 Plasminogen Supplementation Therapy May Be a Good Add-On for the Treatment of IPF Exacerbations/ J. Parker, L. Geerts, A. Laverdure, M. Tremblay, B. Grouix, W. Gagnon, A. Felton, M. Leduc, P. Laurin, L. Gagnon, Laval, Canada, p.A5251 P293 Antifibrotic Effect of PBI-4050 in Human Normal and IPF Lung Fibroblasts, and in AdTGF-b1-Induced Pulmonary Fibrosis Rat Model/ T. Yanagihara, C. Shimbori, M. Leduc, M.J. Nsaibia, P. Laurin, K. Ask, M.R.J. Kolb, L. Gagnon, Hamilton, Canada, p.A5252 Facilitator : R.S. Knipe, MD, Boston, MA P294 Aurora Kinase B Is a Positive Regulator of Proliferation and Survival of Lung-Resident Fibroblasts in Severe Fibrotic Lung Disease/ R.K. Kasam, B.R. Geereddy, V. Sontake, A. Jegga, S.K. Madala, Cincinnati, OH, p.A5253 P295 Loss of Twist1 Expression in the Macrophage Compartment Leads to Multinucleated Giant Cells and Increased Fibrosis in Experimental Lung Injury/ J. Dutta, J. Tan, H. Bahudhanapati, D. Kass, Pittsburgh, PA, p.A5254 P296 Lower Levels of Serum Klotho Is Associated with Decreased Lung Function Tests in Individuals with Interstitial Lung Abnormalities/ N. Machuca Vivas, M. Maldonado, I. Buendía-Roldán, J. Castillo, M. Mejia, M. Selman, Mexico City, Mexico, p.A5255 P297 Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy/ E. Bargagli, L. Bergantini, P. Cameli, M. D’alessandro, L. Bini, P. Rottoli, C. Landi, Siena, Italy, p.A5256 P298 Endothelial Cell-Derived Microparticles as a Biomarker in Pulmonary Fibrosis: A Pilot Study/ T. Neri, L. Tavanti, S. De Magistris, S. Lombardi, C. Romei, A. Palla, P. Paggiaro, A. Celi, Pisa, Italy, p.A5257 P299 Common and Distinct Transcriptome and Proteome Expression Patterns from Lungs in Idiopathic Pulmonary Fibrosis (IPF) and Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)/ S. Matson, J.S. Lee, W. Ren, H.R. Collard, M.A. Matthay, N. Achtar-Zadeh, P.J. Wolters, K. Hansen, O. Eickelberg, Aurora, CO, p.A5258 P300 Bronchoalveolar Cell Transcriptome of Acute Exacerbation in Idiopathic Pulmonary Fibrosis/ A. Prasse, B. Jäger, J.C. Schupp, N. Kaminski, A. Carleo, Hannover, Germany, p.A5259 P301 Pre-Clinical GMP Toxicology Study for the Drug Development of Idopathic Pulmonary Fibrosis (IPF) Using a Novel RNAi-Based Nanoparticle Technology (SAMiRNATM)/ T. Kim, Daejeon, 306-220, Korea, Republic of, p.A7405 P302 Mitotropic Nanocarrier for Targeted Drug Delivery in Senescent Idiopathic Pulmonary Fibrosis Fibroblasts/ S. Bui, M. Paige, L. Rodriguez, S.D. Nathan, G. Grant, Manassas, VA, p.A7406 ATS 2019 • Dallas, TX 272 TUESDAY • MAY 21